Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Pbm Transparency topic
No spam. Unsubscribe anytime.
Heated debate stalls PBM transparency and optimized sourcing bill; committee postpones HB 10‑56 indefinitely
Summary
After hours of testimony from patient groups, pharmacists, employers and consultants, the committee voted down moving HB 10‑56 and then postponed the bill indefinitely. Supporters urged transparency and access to lawful optimized sourcing; opponents warned of patient safety risks, importation and delays in care.
House Bill 10‑56, a contested bill to require pharmacy benefit transparency and to prohibit knowingly false or misleading statements about lawful prescription drug optimized sourcing, generated several hours of testimony and a deep split among stakeholders before the Health & Human Services Committee ultimately failed to move the bill and then postponed it indefinitely.
Sponsor Representative De Grama described the bill’s aim as protecting fiduciaries — the parties legally responsible for plan stewardship — by guaranteeing access to detailed financial and claims information and by preventing parties from knowingly making false statements about lawful options for sourcing prescription drugs. Proponents — including health‑care consultants, employers and several invited experts — argued that PBMs can withhold or obfuscate data and that lawful optimized sourcing (including personally authorized importation under applicable federal authorities) can reduce costs for self‑funded employers while preserving safety and continuity of care.
Patient groups, clinicians, pharmacists and supply‑chain integrity experts mounted sustained opposition. Witnesses from Lupus Colorado, the National Multiple Sclerosis Society, bleeding‑disorders and HIV/AIDS advocacy groups described real patient harms tied to alternative pharmacy programs (they called them AFPs or pharmacy stewardship programs): delays of weeks to months to receive specialty therapies, forced transfer of personal information to third parties, and cases of denial or interruption of needed medications. Pharmacists and the Partnership for Safe Medicines warned that federal law does not authorize wholesale commercial importation and that programs promising imported supply could operate outside lawful FDA pathways. They cautioned the bill could inadvertently legitimize risky commercial importation and chill safety communications.
Committee action: After extended debate and an offered amendment (moving enforcement and some provisions into Title 6), the committee took a roll call on moving the bill; the motion failed on the roll (recorded as 2‑10 with one excused). Vice Chair Leader then moved to postpone indefinitely (by reverse order), and the committee approved that motion without objection, effectively ending HB 10‑56’s progress in this committee.
Why it matters: The debate highlights a deep policy split — whether state law should protect employer fiduciaries and lawful sourcing options by prohibiting misinformation, or whether such statutes risk endorsing untested sourcing models and exposing vulnerable patients to delays and safety risks. Stakeholders raised legal and operational questions that committee members found unresolved.
Documentation: The committee record shows extensive written and oral testimony from both sides and a final vote failing movement of the bill, followed by indefinite postponement.
